KROS Debt-to-Equity Ratio Analysis

Keros Therapeutics’ debt-to-equity ratio of 0.06x means the company uses very little borrowed money compared to the money shareholders have invested — a low figure that typically signals lower financial risk.

This places Keros far below the healthcare sector median of 0.45x, ranking it in the 21st percentile among its peers, meaning only about one-fifth of similar companies carry less debt. Trend data is not available: the year-over-year change, quarter-over-quarter change, and the last eight quarters of history are all listed as N/A, so no directional observation can be made. With a very low ratio but no trend to confirm stability or improvement, the risk profile appears conservative, yet the absence of historical context limits the ability to assess whether this level is intentional or temporary. This metric supports the overall NEUTRAL verdict because the low leverage is favorable for risk-averse investors, but without trend evidence or a clear catalyst, it does not justify a bullish or bearish tilt on its own.

Frequently Asked Questions

Closest Sector Peers